Effects of Acetazolamide on Ventilatory, Cerebrovascular, and Pulmonary Vascular Responses to Hypoxia
- 1 February 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 175 (3) , 277-281
Abstract
Rationale: Acute mountain sickness (AMS) may affect individuals who (rapidly) ascend to altitudes higher than 2,000–3,000 m. A more serious consequence of rapid ascent may be high-altitude pulmonary edema, a hydrostatic edema associated with increased pulmonary capillary pressures. Acetazolamide is effective against AMS, possibly by increasing ventilation and cerebral blood flow (CBF). In animals, it inhibits hypoxic pulmonary vasoconstriction. Objectives: We examined the influence of acetazolamide on the response to hypoxia of ventilation, CBF, and pulmonary vascular resistance (PVR). Methods: In this double-blind, placebo-controlled, randomized study, nine subjects ingested 250 mg acetazolamide every 8 h for 3 d. On the fourth test day, we measured the responses of ventilation, PVR, and CBF to acute isocapnic hypoxia (20 min) and sustained poikilocapnic hypoxia (4 h). Ventilation was measured with pneumotachography. Hypoxia was achieved with dynamic end-tidal forcing. The maximum pressure difference across the tricuspid valve (ΔPmax, a good index of PVR) was measured with Doppler echocardiography. CBF was measured by transcranial Doppler ultrasound. Results: In normoxia, acetazolamide increased ventilation and reduced ΔPmax, but did not influence CBF. The ventilatory and CBF responses to acute isocapnic hypoxia were unaltered, but the rise in ΔPmax was reduced by 57%. The increase in ΔPmax by sustained poikilocapnic hypoxia observed after placebo was reduced by 34% after acetazolamide, the ventilatory response was increased, but the CBF response remained unaltered. Conclusions: Acetazolamide has complex effects on ventilation, PVR, and CBF that converge to optimize brain oxygenation and may be a valuable means to prevent/treat high-altitude pulmonary edema.Keywords
This publication has 37 references indexed in Scilit:
- Pulmonary vasodilation by acetazolamide during hypoxia is unrelated to carbonic anhydrase inhibitionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Physiological aspects of high-altitude pulmonary edemaJournal of Applied Physiology, 2005
- Acetazolamide prevents hypoxic pulmonary vasoconstriction in conscious dogsJournal of Applied Physiology, 2004
- Ventilatory, cerebrovascular, and cardiovascular interactions in acute hypoxia: regulation by carbon dioxideJournal of Applied Physiology, 2004
- Spatial distribution of hypoxic pulmonary vasoconstriction in the supine pigJournal of Applied Physiology, 2004
- Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K + ‐deficient ratsThe FASEB Journal, 2004
- In vivo evidence for KCa channel opening properties of acetazolamide in the human vasculatureBritish Journal of Pharmacology, 2001
- Indexes of Flow and Cross-sectional Area of the Middle Cerebral Artery Using Doppler Ultrasound During Hypoxia and Hypercapnia in HumansStroke, 1996
- Enhancement of Hypoxic Pulmonary Vasoconstriction by Metabolic Acidosis in DogsAnesthesiology, 1990
- Usual clinical dose of acetazolamide does not alter cerebral blood flow velocityRespiration Physiology, 1988